Supporting people with T2DM with education and titration tools may empower them to optimize basal insulin self-titration in order to reach glycemic targets. Three multicenter, randomized, open-label, parallel-group studies have investigated self-titration (supported by either a paper algorithm, web tool or device) vs. physician-led titration in people with T2DM, switching to or initiating Gla-300 (TAKE CONTROL and AUTOMATIX) or Gla-100 (INNOVATE). Fasting blood glucose targets for self-titration were 80-130 mg/dL (4.4-7.2 mmol/L) in TAKE CONTROL and 90-130 mg/dL (5.0-7.2 mmol/L) in both INNOVATE and AUTOMATIX. Self-titration resulted in greater or similar mean HbA1c reductions from baseline vs. physician-led titration (Table). By using self-titration with Gla-300, more people with T2DM achieved fasting glucose targets without confirmed or severe hypoglycemia vs. physician-led titration (TAKE CONTROL and AUTOMATIX). Severe hypoglycemia and other safety outcomes were similar between titration arms in all 3 studies. Self-titration with Gla-300 and Gla-100 using either a paper or device-based algorithm resulted in improved or similar reductions in HbA1c, without an increased risk of hypoglycemia or safety concerns.
M. Kvapil: None. M. Bonnemaire: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. H. Goyeau: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. N. Papanas: None. L. Popescu: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. B. Schultes: Advisory Panel; Self; Novo Nordisk A/S, Sanofi, AstraZeneca, Eli Lilly and Company, Bayer AG, Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Sanofi, Eli Lilly and Company, MSD K.K., Bayer AG, Boehringer Ingelheim GmbH. J. Sieber: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. L. Duvnjak: None.